PHA Classroom banner

PHA Classroom has moved! Visit

>> Back to Recordings

History of PH: Progress in Clinical Management

March 25, 2014

This interactive discussion on the history of pulmonary hypertension (PH) is the second presentation of a two-part series, and focuses on the progress in clinical management of PH. The webinar consists of an interview with a panel of experts considered to be among the founders of the modern PH field.

View the first webinar in the series, History of PH: Mechanisms and Physiology.

Presenter Information


David Badesch, MD
University of Colorado, Denver
David Badesch, MD, is Professor of Medicine in the Divisions of Pulmonary Sciences & Critical Care Medicine and Cardiology at the University of Colorado, Denver, as well as Director of the Pulmonary Hypertension Program at the University of Colorado Health, Denver. Dr. Badesch received his MD at the University of Virginia School of Medicine, and went on to complete his residency in internal medicine at Vanderbilt University School of Medicine. He completed his fellowship in pulmonary medicine at the University of Colorado, School of Medicine. Dr. Badesch has served on the steering committee in multiple studies dealing with pulmonary vascular disease, and published many scholarly articles and abstracts. Dr. Badesch is a member of PHA’s PH Clinicians and Researchers, has served on PHA’s Board of Trustees, received the Outstanding Physician Award from the PHA in 2002, has served as Chair of PHA’s Scientific Leadership Council (SLC), and currently serves a Distinguished Advisor to the SLC.

Stephen Mathai, MD, MHS
Johns Hopkins University School of Medicine
Stephen C. Mathai, MD, MHS, is Assistant Professor in the Division of Pulmonary and Critical Care at Johns Hopkins University School of Medicine. Dr. Mathai received his MD at Jefferson Medical College, and went on to complete his internship, residency and chief medical residency at Thomas Jefferson University Hospital. He then completed his fellowship in pulmonary and critical care medicine at Johns Hopkins University School of Medicine and his MHS in clinical investigation at Johns Hopkins Bloomberg School of Public Health. He has authored and reviewed many scholarly publications and serves as investigator in many research studies. Dr. Mathai is a current member of PHA’s Scientific Leadership Council.

Michael McGoon, MD
Mayo Clinic
Michael McGoon, MD, is Professor of Medicine and Consultant in Cardiovascular Diseases at Mayo Clinic, Rochester, Minnesota. Dr. McGoon attended medical school and completed internship at Johns Hopkins before transferring to Mayo for residency and cardiology training. Dr. McGoon served as Director of the PH Center at Mayo since he initiated it in 1996 until 2007. He is board certified in Internal Medicine and Cardiology. For over 25 years, he has led multiple clinical trials of PH medications, starting with intravenous prostacyclin.  He recently served as chair of the Steering Committee of the REVEAL registry. Dr. McGoon is a member of PHA’s PH Clinicians and Researchers and has been a member of PHA’s Scientific Leadership Council since 1994, serving as Chair from 2002 to 2004 and as a Distinguished Advisor since 2004. He was Chair of the Board of Trustees of PHA (2006-2008), and currently chairs the Pulmonary Hypertension Care Centers Oversight Committee.

Stuart Rich, MD
University of Chicago
Stuart Rich, MD, is Professor of Medicine at the University of Chicago, and a faculty member of the Center for Pulmonary Hypertension within the Section of Cardiology. His research and clinical efforts have led to the discovery of more effective treatments for PH, including the use of medicines like anticoagulants, calcium channel blockers, and prostacyclins. He was principle investigator for the NIH Registry on primary PH, the first of its kind, and has been the leader of the largest clinical center in the US for evaluating and treating PH patients since 1980. He has published hundreds of clinical articles and book chapters on pulmonary heart disease, is currently the Chairman of the Board of the Pulmonary Vascular Research Institute, and a member of the FDA Cardiovascular and Renal Drugs Advisory Committee. He is a member of PHA’s PH Clinicians and Researchers and is a former member of PHA’s Scientific Leadership Council.

FacebookTwitterInstagram iconLinkedInYouTube

For optimal viewing of, please use a standards-compliant browser such as Google Chrome or Firefox.

The information provided on the PHA website is provided for general information only. It is not intended as legal, medical or other professional advice, and should not be relied upon as a substitute for consultations with qualified professionals who are familiar with your individual needs.

801 Roeder Road, Ste. 1000, Silver Spring, MD 20910   Patient-to-Patient Support Line: 1-800-748-7274
    Privacy Policy    Provide Feedback & Report Bugs

Designed by Matrix Group International, Inc.® | © 2016 Pulmonary Hypertension Association. All Rights Reserved.


The National Organization for Rare Disorders (NORD) awarded PHA the Abbey S. Meyers Leadership Award in 2012 for outstanding service to PHA members in advocacy, education and other key areas.